Heart protection during lymphoma chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Injuries & trauma clinical trials.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called diffuse large B-cell lymphoma or a related high-grade B-cell lymphoma.
- You are scheduled to receive chemotherapy with R-CHOP or pola-R-CHP.
- You have not had chemotherapy for this lymphoma before.
- You are 18 years or older.
- You have at least one heart risk factor: weak heart pumping function (LVEF 30-50%), a history of heart failure, or past exposure to a similar chemotherapy drug.
- You are not pregnant and agree to use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a simple “remote conditioning” treatment on the arm can help protect the heart while you receive chemotherapy that includes anthracyclines. If you’re at higher risk for heart damage from chemo, this may reduce risk and help monitor heart function over time.
This study tests whether a heart-protective medication called sotagliflozin can prevent heart damage caused by strong chemotherapy drugs used to treat newly diagnosed lymphoma. You would take this medication during and after your cancer treatment.
This trial tests a structured lifestyle and survivorship care plan for people who finished treatment for certain lymphoma types and are now in long-term remission. The goal is to support long-term health (including heart-related monitoring) and reduce future risks.
This trial tests if the drug dexrazoxane can protect the heart during chemotherapy for a type of lymphoma called DLBCL. It may be an option for patients starting a standard treatment regimen known as R-CHOP.
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.